CyGenica
Main focus: In vitro and in vivo delivery solutions for genome-editing molecules/therapeutics (CRISPR-Cas ribonucleoproteins (RNPs))
Company stage: Pre-clinical
Diseases : Rare cancer (Hairy cell leukaemia), other rare diseases (Cystic Fibrosis, Haemophilia)
Our novel delivery system: Engineered biomolecule (non-viral, non-nanoparticle, non-lipid)
Funding stage: Seed
Location:
CYGENICA LIMITED, 12 South Mall, Co. Cork (Ireland)
R & D Innovation Lab at 700 NIP, NCL Innovation Park, Dr. Homi Bhabha Road, Pashan, Pune – 411 008 (India)
Website: www.cygenica.com
At CyGenica, we focus on enhanced quality of life and improved patient outcome by enabling safe, targeted, and affordable intracellular delivery of therapeutic molecules. Our platform is a non-toxic proprietary engineered biomolecule that works just like a molecular drill. It bores through the cell membrane to deliver molecular cargoes to the nucleus without causing any harm to the cell, thus solving the most crucial issue of targeted intracellular delivery. We use our platform to develop in vitro and in vivo delivery solutions with a particular focus on cancer therapies and gene-editing components (CRISPR-Cas ribonucleproteins (RNPs)).